

**Table 1: Taranaki region hospital cumulative antibiotic susceptibilities 2022 (antibiogram)**

Organism group	No. tested	Numbers denote % susceptible												Second line/ restricted antibiotics <sup>1</sup>						
		Antibiotics in common usage																		
		Penicillin	Ampicillin	Amoxi-clav	Flucloxacillin	Cephalexin	Cefuroxime	Erythromycin	Co-trimoxazole	Doxycycline	Ceftriaxone	Trimethoprim <sup>2</sup>	Nitrofurantoin <sup>2</sup>	Clindamycin	Ciprofloxacin	Ceftazidime	Piperacillin-tazo	Meropenem	Gentamicin	Vancomycin
<b>Non-urine isolates</b>																				
<i>Staphylococcus aureus</i> (8% MRSA)	628				92		92	88	99	96				89						
<i>Strep pyogenes</i> (GAS) and <i>Strep agalactiae</i> (GBS) <sup>4</sup>	21	100						86						95						
<i>Haemophilus influenzae</i>	82		55 <sup>#</sup>	65 <sup>#</sup>					71	100										
<i>Pseudomonas aeruginosa</i>	88													89 <sup>#</sup>	91 <sup>#</sup>	95 <sup>#</sup>	97		(96) <sup>§</sup>	
<b>Bacteraemic isolates</b>																				
<i>Escherichia coli</i>	65		49	58					77		95				91		95	100	(97) <sup>§</sup>	
<i>Staphylococcus aureus</i>	53	17			91		91	88	98	98				88						
<i>Pseudomonas aeruginosa</i> <sup>4</sup>	8													88 <sup>#</sup>	100 <sup>#</sup>	100 <sup>#</sup>	100		(100) <sup>§</sup>	
Beta haemolytic streptococci Groups, A, B, C and G <sup>4</sup>	25	100						72						72						
<i>Streptococcus pneumoniae</i> <sup>4</sup>	12	100	100					100		100										
<i>Streptococcus pneumoniae meningitis breakpoint</i> <sup>4</sup>	12	100	100					100		100										
<i>Enterococcus</i> spp <sup>4</sup>	10		90																100	
<b>Urine isolates</b>																				
<i>E coli</i> (ESBL 3%)	769		59			93				80	100							(95) <sup>§</sup>		
<i>Klebsiella pneumoniae</i> (ESBL 5%)	85		0			96				91	NR							(98) <sup>§</sup>		
<i>Enterococcus</i> spp	88		92															100		
<i>Pseudomonas aeruginosa</i>	45													87 <sup>#</sup>	87 <sup>#</sup>	96 <sup>#</sup>	96		(89) <sup>§</sup>	

<sup>1</sup>Not recommended for first line use unless recommended by ID/Micro; second line antibiotics are selectively tested on lower numbers of more resistant isolates.

<sup>2</sup>Recommended for uncomplicated UTI isolates only.

<sup>3</sup>Includes community isolates

<sup>4</sup>Caution - only a very small number of isolates

R = always resistant

NR = not recommended

<sup>#</sup>reported as susceptible increased exposure

<sup>§</sup>Bracketed "susceptibility" indicates % wild-type (i.e no detectable resistance mechanism) but this drug-bug combination is not recommended unless combined with another effective measure (eg surgical debridement/another susceptible agent).

Table 2: Taranaki region community cumulative antibiotic susceptibilities 2022 (antibiogram)

Organism group	Number tested	Antibiotics in common usage									
		Penicillin	Amoxicillin	Amoxi-clav	Amoxi-clav cystitis	Flucloxacillin	Cephalexin	Erythromycin	Co-trimoxazole	Doxycycline	Trimethoprim <sup>1</sup>
<b>Non urinary sites</b>											
<i>Staphylococcus aureus</i> (all)	771	17			94		89	99	97		
Methicillin-resistant <i>Staph aureus</i> (MRSA, 6%)	49				0		80	100	78		
<i>Streptococcus pneumoniae</i> <sup>2</sup>	31	89	90				90	74	87		
<i>Haemophilus influenzae</i>	49		63 <sup>#</sup>	78 <sup>#</sup>				78	98		
<b>Urine isolates</b>											
<i>E coli</i>	1823		64			95		80	80	99	
<i>Klebsiella pneumoniae</i>	128		0			96		87	87	NR	
<i>Staphylococcus saprophyticus</i>	96		94						94	100	
<i>Proteus mirabilis</i>	84		92			98			79	R	

<sup>1</sup> Recommended for uncomplicated UTI only

R = always resistant

NR = not recommended

<sup>2</sup> Combined 2021 and 2022 data

# reported as susceptible, increased exposure